NCT02740634 Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
| NCT ID | NCT02740634 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Atypical Alzheimer's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2016-05 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2016-05 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Eligibility Criteria
Inclusion Criteria: * Over the age of 21 * Must have an informant who will be able to provide independent evaluation of functioning * English is primary language * All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). * All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language * All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain Exclusion Criteria: * If you have had a stroke or tumor that could explain your symptoms * Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study * Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded * Subjects will be excluded if they have poor vision (20/400) * Women that are pregnant or post-partum and breast-feeding will be excluded * Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)
Contact & Investigator
Jennifer Whitwell, Ph.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT02740634 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 80 Years, studying Atypical Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02740634 currently recruiting?
Yes, NCT02740634 is actively recruiting participants. Contact the research team at boland.sarah@mayo.edu for enrollment information.
Where is the NCT02740634 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT02740634 clinical trial?
NCT02740634 is sponsored by Mayo Clinic. The principal investigator is Jennifer Whitwell, Ph.D. at Mayo Clinic. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.